Jonathan McWilliam

 May 08, 2023, 16:05 ET  – Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET – Topline data from AHFIRM trial expected in 2H 2023 CUPERTINO, Calif., May 8, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2023 and provided a corporate update. …

DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update Read More »

 May 01, 2023, 19:03 ET  CUPERTINO, Calif., May 1, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023. Monday, May 8 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free:  …

DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8 Read More »

 Apr 27, 2023, 17:11 ET  CUPERTINO, Calif., April 27, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader (“KOL”) event on Alcohol-Associated Hepatitis on May 16th in New York City. Topics of discussion will include the etiology and prevalence of alcohol-associated hepatitis (AH), current treatment insufficiencies and unmet …

DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis Read More »

 Apr 25, 2023, 18:45 ET  CUPERTINO, Calif., April 25, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Managing Director, Senior Biotechnology Research Analyst, H.C Wainwright & Co., LLC at the H.C. Wainwright BioConnect Investor Conference on May …

DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference Read More »

 Apr 10, 2023, 06:00 ET  Data expands upon previously reported results, including individual patient data, additional liver biomarkers, and comparisons to matching arms from a contemporaneous study Company on track to report data from ongoing Phase 2b AHFIRM trial in 2H 2023 CUPERTINO, Calif., April 10, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical …

DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis Read More »

 Mar 21, 2023, 16:30 ET  CUPERTINO, Calif., March 21, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election …

DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board Read More »

 Mar 09, 2023, 08:30 ET  CUPERTINO, Calif., March 9, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the …

DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference Read More »

 Mar 07, 2023, 16:05 ET  –  Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET –  Topline data from AHFIRM trial expected in 2023 CUPERTINO, Calif., March 7, 2023 /PRNewswire / — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2022 and provided a …

DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update Read More »

 Feb 28, 2023, 18:07 ET  CUPERTINO, Calif., Feb. 28, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023. Tuesday, March 7 @ 4:30pm Eastern Time / 1:30pm Pacific …

DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7 Read More »

 Feb 03, 2023, 17:17 ET  CUPERTINO, Calif., Feb. 3, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) (“DURECT”), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and …

DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants Read More »